Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Aapro

Showing results (81-90 of 138) with videos related to

Pageof 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2017
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomitingG Dranitsaris, A Molassiotis, M Clemons, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancerM Aapro, F Andre, K Blackwell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)L Biganzoli, A Goldhirsch, C Straehle, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patientsJ F Kessler, D S Alberts, P M Plezia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 28, 2014
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysisM Aapro, V Moebus, U Nitz, et al.
ESMO Open|September 18, 2025
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug developmentS Champiat, K Ouali, A Laparra, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?M Aapro, C J H van de Velde, C Markopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2018
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxaneM Martin, M Campone, I Bondarenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
Reply to letter to the editor 'Primum non nocere' by Templeton and ŠerugaM Aapro, V Moebus, U Nitz, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 21, 2023
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agentsJørn Herrstedt, L Celio, P J Hesketh, et al.
Pageof 14

Showing results (81-90 of 138) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2017
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomitingG Dranitsaris, A Molassiotis, M Clemons, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancerM Aapro, F Andre, K Blackwell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)L Biganzoli, A Goldhirsch, C Straehle, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
An effective five-drug antiemetic combination for prevention of chemotherapy-related nausea and vomiting. Experience in eighty-four patientsJ F Kessler, D S Alberts, P M Plezia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 28, 2014
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysisM Aapro, V Moebus, U Nitz, et al.
ESMO Open|September 18, 2025
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug developmentS Champiat, K Ouali, A Laparra, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?M Aapro, C J H van de Velde, C Markopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2018
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxaneM Martin, M Campone, I Bondarenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
Reply to letter to the editor 'Primum non nocere' by Templeton and ŠerugaM Aapro, V Moebus, U Nitz, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 21, 2023
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agentsJørn Herrstedt, L Celio, P J Hesketh, et al.
Pageof 14